CHEMOSEN3D INC

HOUSTON, TX · Biotech · Private

Magnetic 3D ex vivo assay platform for testing anti-cancer drug sensitivity per patient

Claim this profile

Follows are private to you and power your alerts

Updated · chemosen3d.com

Sector
Biotech
Headquarters
HOUSTON, TX
Latest Form D
$165K, Feb 2021
Total capital
$341K
Federal grants
$176K
1 award · 2018
Rank in peer group#21 of 22
Private capital raised
$165K
1 Form D · last Feb 2021
68 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

2018201920202021FEDERAL ↑EQUITY ↓Cumulative $341K$176K1st Form D$165K
2018201920202021FEDERAL ↑EQUITY ↓Cumulative $341K$176K1st Form D$165K

Latest events

  • Private capital raisedForm D · SEC · 1st filing$165K
  • Federal grantHealth and Human S · Phase I · Numeric Expansion of CD-19 Specific T cells in Magnetic 3D Culture$176K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

37months

from CHEMOSEN3D INC’s first federal award to its first private round.

First federal award · Feb 2018
Health and Human S · $176K
First Form D · Feb 2021
$165K · 1st Form D
Awards before first raise
1 award

An association in public records, not a cause or a prediction.

Standing among 22 peers

Line = median

Biotech · Device

  • Federal grantsBelow median

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Chad BrinkleyExecutive Officer, DirectorNamed in SEC Form D filings
  • Glauco R. SouzaDirectorNamed in SEC Form D filings
  • Matthew R. LenhartDirectorNamed in SEC Form D filings
  • Thomas C. KillianDirectorNamed in SEC Form D filings
  • Tim R. McGrathDirectorNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • Nymirum, Inc.Similar federal contract value in Biotech · null in contracts
  • Covira SurgicalSimilar federal contract value in Biotech · null in contracts
  • REGENTIS BIOMATERIALS LTD.Similar federal contract value in Biotech · null in contracts
  • Talapo TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • RAINBIO, INC.Similar federal contract value in Biotech · null in contracts
  • LACTIGA US INC.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .